NIH Alzheimer’s Research Summit 2021

From the NIH

Reading Time: 7 minutes

The 2021 NIH Alzheimer’s Research Summit is a key strategic planning meetings tied to the implementation of the first goal of the US National Plan to Address Alzheimer’s Disease: to effectively treat and prevent Alzheimer’s disease by 2025.

They bring together a multi-stakeholder community including government, industry, academia, private foundation, and patient advocacy groups, to further integrated, translational Alzheimer’s research. The goal is to accelerate the development of effective, disease-modifying, and palliative therapies for the cognitive as well as neuropsychiatric symptoms of Alzheimer’s disease.The 2021 Summit builds on the foundation laid through the work of the 2012, 2015, and 2018 summit participants. Over the course of the Summit, a global audience of researchers and the public will have an opportunity to contribute individually to the discussions through multiple open forum sessions.

Click here to review the full agenda

2021 NIH Alzheimer’s Research Summit: Agenda

The 2021 Summit will be held as a virtual event April 19- 22, from 10:00 a.m. – 3:30 p.m. EDT. This agenda is subject to change. Read more about the 2021 NIH Alzheimer’s Research Summit: Path to Precision Medicine for Treatment and Prevention.

DAY ONE – Monday, April 19, 2021

10:00 a.m. – 10:45 a.m. Introductory Remarks

  • Francis Collins, Director, NIH
  • Richard Hodes, Director, NIA/NIH
  • Eliezer Masliah, Director, Division of Neuroscience, NIA/NIH

10:45 a.m. – 11:45 a.m. Plenary Talks

Understanding the Impact of Health Disparities to Enable Precision Medicine for Dementia
Lisa Barnes, Rush University

New Mechanistic Insights and Technologies for Precision Medicine Research on Aging and Alzheimer’s
Nathan Price, Onegevity, a division of Thorne HealthTech

11:45 a.m. – 3:30 p.m. SESSION ONE | Deconstructing Disease Complexity: from Populations to Single Cells, from Genes to Multiscale Models

Chairs: Catherine Kaczorowski (Jackson Laboratory) and David Bennett (Rush University)


  • Resolving the Complex Genetics of Alzheimer’s
    Alison Goate, Icahn School of Medicine at Mount Sinai
  • Developing Multiscale Models of Alzheimer’s Risk and Resilience
    Philip De Jager, Columbia University
  • Single-cell Dissection of Human Disease Circuitry in Neurodegeneration
    Manolis Kellis, Massachusetts Institute of Technology
  • Molecular Basis of the Clinical Heterogeneity in Early-Onset AD
    Jennifer Yokoyama, University of California, San Francisco
  • Mapping the Molecular Trajectories of Aging to Understand Mechanisms of Neurodegeneration
    Tony Wyss-Coray, Stanford University
  • A Tale of Two Systems: Lessons from Mid-Life Aging with Implications for Alzheimer’s Prevention and Treatment
    Roberta Diaz Brinton, University of Arizona

Lightning Round Presentations

  • Dena Dubal, University of California, San Francisco
  • Ivan Nalvarte, Karolinska Institute
  • Guojun Bu, Mayo Clinic
  • Matthias Arnold, Helmholtz University
  • Morgan Levine, Yale University
  • Vilmundur Gudnason, Iceland Heart Association
  • Panos Roussos, Icahn School of Medicine at Mount Sinai
  • Vilas Menon, Columbia University
  • Ed Lein, Allen Brain Institute
  • Paul Thompson, University of Southern California

2:45 p.m. – 3:30 p.m. Moderated Discussion and Open Forum

DAY TWO – Tuesday, April 20, 2021

10:00 a.m. – 12:30 p.m. SESSION TWO | Enabling Infrastructure and Incentives to Improve Research Rigor, Reproducibility and Translatability

Chairs: Lara Mangravite (Sage Bionetworks) and Stacey Rizzo (University of Pittsburgh)


  • Enhancing Reproducibility and Rigor in Animal Research
    Lawrence Tabak, NIH
  • AD Knowledge Portal and Agora: an Integrated FAIR Data Infrastructure for Aging and Dementia Research
    Anna Greenwood, Sage Bionetworks
  • NIAGADS Data Resources and Harmonization of AD Genetic, Epidemiologic and Clinical Data
    Li-San Wang, University of Pennsylvania and Timothy Hohman, Vanderbilt University
  • NCRAD: Biobanking to Enable Reproducible Precision Medicine Research in AD and Related Dementias
    Tatiana Foroud, Indiana University
  • Improving Preclinical to Clinical Translation: AlzPED and MODEL-AD Preclinical Efficacy Testing Pipeline
    Stacey Rizzo, University of Pittsburgh

11:15 a.m. – 11:45 a.m. Open Forum

11:45 a.m. – 12:30 p.m. FUNDERS FORUM | Aligning Funding Incentives to Promote Transparent, Reproducible and Collaborative Research

Moderator: Suzana Petanceska, NIA

  • Katja Brose, Chan Zuckerberg Initiativen
  • Todd Sherer, Michael J. Fox Foundation
  • Howard Fillit, Alzheimer’s Drug Discovery Foundation
  • Penny Dacks, Association for Frontotemporal Degeneration
  • Angela Taylor, Lewy Body Dementia Association
  • Tetsuyuki Maruyama, Alzheimer’s Disease Data Initiative
  • Heather Snyder, Alzheimer’s Association

12:30 p.m. – 12:45 p.m. Break

12:45 p.m. – 3:30 p.m. SESSION THREE | Accelerating Therapy Development: Open Science from Targets to Trials

Chairs: Rebecca Edelmayer (Alzheimer’s Association) and Maria Quinton (Takeda)


  • AMP AD Target Discovery Program
    Nilufer Ertekin-Taner, Mayo Clinic
  • Accelerating Therapy Development for AD/ADRD Through the MODEL-AD Open Science Consortium
    Bruce Lamb, Indiana University
  • TREAT-AD Centers: Accelerating Drug Discovery for Novel Targets through Open Science
    Alan Palkowitz, Indiana University
  • Raising the Bar on Data Sharing in Clinical Trials
    Reisa Sperling, Brigham and Women’s Hospital, Harvard University Paul Aisen, University of Southern California
  • Open Drug Discovery – A Path to Generate New, Affordable Medicines for Alzheimer’s Disease
    Aled Edwards, Structural Genomics Consortium, University of Toronto

2:00 p.m. – 2:45 p.m. PANEL DISCUSSION | From Open Science to Open Drug Development

Moderator: Rebecca Edelmayer, Alzheimer’s Association

  • Lara Mangravite, Sage Bionetworks
  • Guy Rouleau, The Neuro, McGill University
  • Richard Gold, McGill University
  • Peter Lansbury, Bial Biotech
  • Kalpana Merchant, Northwestern University
  • Billy Dunn, FDA

2:45 p.m. – 3:30 p.m. Open Forum

DAY THREE – Wednesday, April 21, 2021

10:00 a.m. – 12:45 p.m. SESSION FOUR | Diversifying the Therapeutic Pipeline to Develop Precision Medicines

Chairs: Frank Longo (Stanford University) and Kelly Bales (Voyager Therapeutics)


  • Delivering Probes and Clinical Candidates to Test Precision Medicine Therapeutic Hypotheses in AD
    Martin Watterson, Northwestern University
  • Targeting the Epichaperome in AD
    Gabriela Chiosis, Memorial Sloan Kettering Cancer Center
  • Developing MAS Receptor Agonists for the Treatment of Cognitive Impairment in AD and VCID
    Meredith Hay, University of Arizona
  • Stem-Cells Based Therapy for AD
    Lisa McGinley, University of Michigan
  • Biologic and Small Molecule Strategies Targeting Pyroglutamate Amyloid Beta for the Treatment of AD
    Cynthia Lemere, Harvard University

Lightning Round Presentations

  • Susan Catalano, Cognition Therapeutics
  • Michael Agadjanyan, Institute for Molecular Medicine
  • Eugenia Trushina, Mayo Clinic
  • Pam Maher, Salk Institute
  • May Khanna, University of Arizona
  • Dani Brunner, PsychoGenics
  • Jinhe Li, Green Valley

11:30 a.m. – 12:00 p.m. Open Forum

12:00 p.m. – 12:45 p.m. PANEL DISCUSSION | Diversifying the Translational Workforce and Clinical Trials Recruitment

Moderators: Laurie Ryan, NIA and Michelle Jones-London, NINDS

  • Rema Raman, University of Southern California
  • May Khanna, University of Arizona
  • Stephanie Monroe, UsAgainstAlzheimer’s
  • Jonathan Jackson, Harvard University
  • Gerren Wilson, Genentech
  • Carl Hill, Alzheimer’s Association

12:45 p.m. – 1:00 p.m. Break

1:00 p.m. – 3:30 p.m. SESSION FIVE | Emerging Biomarkers Landscape

Chairs: Andrew Saykin (Indiana University) and Susan Catalano (Cognition Therapeutics)


  • Session Opening Remarks: Developing Biomarkers to Enable Precision Medicine for Dementia
    Janet Woodcock, FDA
  • Innovating Methods for Developing New PET Ligands for Neurological Disorders
    Neil Vasdev, Centre for Addiction and Mental Health, University of Toronto
  • Evaluating AT(N) in Diverse Cohorts and in Down Syndrome
    Sid O’Bryant, University of North Texas Health Science Center
  • New Plasma Tau Biomarkers
    Oskar Hansson, Lund University
  • Round Robin Trials to Validate Plasma ATN Assays
    Henrik Zetterberg, University of Gothenburg
  • Discovery of Omics Biomarkers for Patient Stratification
    Nicholas Seyfried, Emory University
    Rima Kaddurah-Daouk, Duke University
  • Digital Biomarkers
    Graham Jones, Novartis
    Rhoda Au, Boston University

2:45 p.m. – 3:30 p.m. Moderated Discussion and Open Forum

DAY FOUR – Thursday, April 22, 2021

10:00 a.m. – 12:30 p.m. SESSION SIX | Advancing Drug Repurposing and Combination Therapy Development

Chairs: Marina Sirota (University of California, San Francisco) and Roberta Diaz Brinton (University of Arizona)


  • Low Dose Levetiracatem Formulation to Slow the Progression of MCI in AD
    Richard Mohs, AgeneBio
  • ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer’s Disease
    Marina Sirota, University of California, San Francisco
  • Harnessing Network Medicine for Alzheimer’s Drug Repurposing
    Feixiong Cheng, Cleveland Clinic Lerner Research Institute
  • Leveraging the Human Non-Coding Transcriptome and Deep Learning to Advance Drug Repurposing for AD
    Claes Wahlestedt, University of Miami
  • A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer’s Disease
    Robert Rissman, University of California, San Diego
  • Using Virtual Reality to Advance Combination Therapy for MCI
    Judy Pa, University of Southern California
  • Personalized Multidomain Approach to Risk Reduction for AD Prevention
    Kristine Yaffe, University of California, San Francisco
  • Non-Pharmacological Interventions for AD Treatment and Prevention in the Era of Precision Medicine
    Laura Baker, Wake Forest University

11:45 a.m. – 12:30 p.m. Moderated Discussion and Open Forum

12:30 p.m. – 12:45 p.m. Break

12:45 p.m. – 3:30 p.m. SESSION SEVEN | Understanding the Impact of the Exposome on Brain Health to Advance Disease Prevention

Chairs: Amy JH Kind (University of Wisconsin) and Rachel Whitmer (University of California, Davis)


  • The Exposome and Health: From Populations to Molecules
    Gary Miller, Columbia University
  • Embedding Mobile Health and Deep Learning into Prospective Cohort Studies
    Peter James, Harvard Medical School and Harvard Pilgrim Health Care Institute and Harvard TH Chan School of Public Health
  • Quantifying the Socioeconomic Impact on Brain Health – The Neighborhood Atlas
    Amy JH Kind, University of Wisconsin
  • The Impact of Experiential and Lifestyle Factors on Cognitive Decline and Dementia
    David Bennett, Rush University
  • The Role of the Microbiome in Aging and AD: The Alzheimer’s Gut Microbiome Project
    Rob Knight, University of California, San Diego

Lightning Round Presentations

  • Ben Readhead, Arizona State University
  • Hillard Kaplan, Chapman University
  • Jose Luchsinger, Columbia University
  • Lindsay Farrer, Boston University
  • Jennifer Weuve, Boston University
  • Kelly Bakulski, University of Michigan
  • Dana Dolinoy, University of Michigan
  • Karen Block, VA
  • Antony Williams, EPA
  • Chirag Patel, Harvard University

2:30 p.m. – 3:30 p.m. Moderated Discussion and Open Forum

3:30 p.m. – 3:45 p.m. Societal Impact of Increased Funding for Women’s Health Research in AD/ADRD: The Women’s Health Access Matters (WHAM!) Report

  • Meryl Comer, UsAgainstAlzheimer’s
  • Lori Frank, RAND Corporation

3:45 p.m. – 4:00 p.m. Closing Remarks

Allan Levey, Co-Chair, National Alzheimer’s Project Act Advisory Council on Alzheimer’s Research Care and Services

Leave a comment

Your email address will not be published. Required fields are marked *

Get all the support you need sent straight to your inbox. Research news, oppertunities, blogs, podcasts, jobs, events, funding calls and much more – every friday!

No Thanks

Translate »